Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01092065 | Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia | PHASE2 | COMPLETED | 23 | — | — | Mar 1, 2010 | Jul 1, 2011 | Dec 23, 2020 | 4 | United States |
| NCT00888004 | Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients | PHASE2 | COMPLETED | 28 | — | — | Mar 1, 2009 | - | Apr 19, 2016 | 5 | Germany |
| NCT00582673 | Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa | PHASE2 | COMPLETED | 31 | — | — | Oct 1, 2007 | - | May 14, 2010 | 5 | Germany |
| Arm | Type | Description |
|---|---|---|
| AFQ056 100 mg (Bid) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Active | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AFQ056 with L-dopa | DRUG | hard gelatin capsule to be taken bid for six weeks |
| Placebo | DRUG | hard gelatin capsule to be taken bid for six weeks |
| AFQ056 | DRUG | - |
Inclusion Criteria: * Outpatients with Parkinson's Disease (PD), treated with L-dopa, experiencing OFF time and dyskinesias for at least three months Exclusion Criteria: * Surgical treatment for PD * Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has bee...